Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group c polysaccharide-tetanus toxoid conjugate vaccine
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Meningococcal group C polysaccharide-tetanus toxoid conjugate vaccine is a monovalent conjugate vaccine designed to prevent invasive disease caused by *Neisseria meningitidis* serogroup C. The active component is de-O-acetylated group C meningococcal polysaccharide covalently linked to tetanus toxoid protein, which acts as a carrier and enhances immunogenicity. This formulation induces robust antibody responses and long-lasting immunity in infants, children, and adults by stimulating T-cell dependent immune mechanisms. It has been shown to be highly effective in reducing the incidence of serogroup C disease following mass vaccination campaigns[3][4][5]. The primary indication is prevention of invasive meningococcal disease (meningitis and septicemia) due to serogroup C.
- Brand names
- NeisVac-C
- Other names
- meningococcal group C conjugate vaccineMenC-TTGCMP-TT
02
Targets
Neisseria meningitidis group C capsular polysaccharideTT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal group c polysaccharide-tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group c polysaccharide-tetanus toxoid conjugate vaccine.